Conference Proceedings

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Youn H Kim, H Miles Prince, Sean Whittaker, Steven M Horwitz, Madeleine Duvic, Oliver Bechter, Jose A Sanches, Rudolf Stadler, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Herbert Eradat, Lauren C Pinter-Brown, Pablo L Ortiz-Romero, Oleg E Akilov, Judith Trotman, Kerry Taylor, Michael Weichenthal, Jan Walewski Show all

BLOOD | AMER SOC HEMATOLOGY | Published : 2018

Abstract

Abstract Background: A histologic finding of large cell transformation (LCT) in Mycosis fungoides (MF) is often associated with an aggressive clinical course and inferior prognosis (Arulogun et al. Blood 2008). In patients (pts) with advanced MF (stage IIB-IV), LCT has been established as an independent prognostic factor (Scarisbrick et al. JCO 2015). Although CD30 expression is observed more frequently in MF with LCT vs without LCT, a wide range of CD30 expression levels is observed in LCT lesions and the level of expression lacks prognostic value for MF (Vergier et al. Blood. 2000). The ALCANZA study (NCT01578499) demonstrated significantly better rates of obj..

View full abstract